News

The BRAF inhibitor encorafenib combined with the MEK inhibitor binimetinib reduced the risk of disease progression or death by 23% compared with single-agent encorafenib for patients with&nbsp;<em>BRAF</em>-mutant melanoma.

John P. Leonard, MD, discusses&nbsp;advancements across hematologic malignancies and pivotal trial data he is anticipating at the 2017 ASCO Annual Meeting.

Pembrolizumab (Keytruda) has been granted an accelerated approval&nbsp;by the FDA for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non&ndash;small cell lung cancer, regardless of PD-L1 expression.

Gail J. Roboz, MD, discusses&nbsp;the recent FDA approval of midostaurin and what else is emerging in the treatment landscape in AML.

Atezolizumab failed to meet the primary endpoint of improving overall survival in the second-line setting for patients with locally advanced or metastatic urothelial carcinoma.

The FDA has given its approval to co-packaging of the oral medications ribociclib (Kisqali) and letrozole (Femara) for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer.

An accelerated approval for the PD-L1 inhibitor avelumab (Bavencio) has been granted by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Matthew I. Milowsky, MD, discusses&nbsp;advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.

Researchers at Vanderbilt University and the University of Leeds in England have successfully performed autonomous retroflexion of a robotic capsule during colonoscopy in a subject animal.

Wolfgang Janni, MD, PhD, discusses&nbsp;toxicity management with neratinib and other agents for HER2-positive breast cancer, as well as emerging treatments and impactful trials in the field.

Steven Coutre, MD,&nbsp;discusses ongoing efforts to enhance frontline outcomes for patients with CLL.

The safety and tolerability of chimeric antigen receptor T-cell therapy is being explored in an ongoing single-arm, phase I clinical trial for patients with advanced non&ndash;small cell lung cancer.

Daniel&nbsp;Morgensztern,&nbsp;MD, discusses&nbsp;both the single-agent and combination immunotherapy data in NSCLC and what researchers are poised to do next in the field.

Adding bevacizumab to standard platinum-based chemotherapy demonstrated a clinically significant improvement in median overall survival in women with recurrent ovarian cancer.

Median overall survival was not improved with&nbsp;zoptarelin doxorubicin, a hybrid molecule combining an LHRH-agonist and doxorubicin, in a phase III advanced endometrial cancer trial.

Pembrolizumab has been approved by the European Commission for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

Ann Marie Beddoe, MD, discusses a study implementing cervical cancer screening and highlights HPV predictors in developing countries.

Women who underwent bariatric surgery to combat obesity were less likely to develop any cancer and also less likely to develop female-specific cancers, acording to study results published in <em>Gynecologic Oncology.</em>

The combination of the investigational agent birinapant and carboplatin could eliminate platinum-resistant, high-grade serous carcinoma (HGSC) ovarian tumor cells, according to preclinical findings published in&nbsp;<em>Precision Oncology.</em>

With a vote of 217 to 213, House Republicans have passed a revised version of the American Health Care Act (AHCA), without any Democratic support, and despite strenuous opposition from the healthcare community.

Richard M. Stone, MD,&nbsp;discusses the impact that midostaurin could have for patients with AML, as well as ongoing research with the agent.

Aarti Bhatia, MD, discusses newer single agents and combination treatments being investigated for patients with head and neck cancer.

David M. Sabatini, MD, PhD, has been declared the winner of the 2017 Lurie Prize in Biomedical Sciences from the Foundation for the National Institutes of Health.

Memorial Sloan Kettering Cancer Center has named Luis A. Diaz, MD, as the head of the Division of Solid Tumor Oncology. He will be taking over the role as the former head of the department, David R. Spriggs, MD, steps down following nearly 13 years of service.

Benjamin L. Judson, MD, highlights the importance of a multidisciplinary team and shares insight on some of the advancements related to surgery for patients with head and neck cancer.

Siddhartha Devarakonda, MD, highlights&nbsp;the importance of testing for molecular markers, some of the rarer mutations, and what work lies ahead for the field of NSCLC.

Debu Tripathy, MD, discusses&nbsp;current and emerging treatment strategies in the neoadjuvant setting for patients with HER2-postive breast cancer.

Lynn Acton, MS, CCC (SLP) discusses&nbsp;the significance of swallowing modalities for patients with head and neck cancer during and after radiation therapy.

NYU Langone&rsquo;s Perlmutter Cancer Center has announced that Ophira Ginsburg, MD, will be director of its new High-Risk Program, which will identify, study, and care for patients with hereditary syndromes that increase their risk for developing cancer.

Nivolumab (Opdivo) demonstrated promise as a second-line therapy for patients with hepatocellular carcinoma (HCC), according to results of the CheckMate-040 trial presented at the 2017 International Liver Congress.